Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Histamine dihydrochloride and IL-2 for AML: impacts for relapse risk and survival

Anna Martner • 25 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Histamine dihydrochloride IL-2

Anna Martner, PhD, of the University of Gothenburg, Gothenburg, Sweden, discusses the mechanism of action of the combination of histamine dihydrochloride and IL-2, and its impacts for relapse risk and survival in acute myeloid leukemia (AML). This interview was held at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Anna Martner

3:21
NOX2: a potential immune checkpoint for inhibition in AML
Anna Martner • 25 Feb 2019
1:50
What are the advantages of using histamine dihydrochloride together with immunotherapy?
Anna Martner • 24 Feb 2017
6:18
Biomarkers for acute myeloid leukemia (AML) – lessons from IL-2 immunotherapy with HDC
Anna Martner • 24 Feb 2017

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals